Advertisement

Regulation of microRNA Expression by Growth Factors in Tumor Development and Progression

Chapter
Part of the Current Human Cell Research and Applications book series (CHCRA)

Abstract

MicroRNAs (miRNAs) are a class of noncoding small RNAs (22–25 nucleotides) that regulate cell proliferation and various cellular functions by interfering with the translation of target messenger RNAs (mRNAs). Altered expression of miRNAs is found in various human malignancies, and indeed, we previously reported that the expression of miR-205 and miR-21 was altered in human head and neck squamous cell carcinoma (HNSCC), by miRNA microarray analysis. We also confirmed that the expression of miR-200c and miR-27b was directly regulated by hepatocyte growth factor (HGF) in HNSCC cell line, HSC3. These results suggest the significance of miRNAs as a key regulatory molecule for achieving various functions of growth factors. Altered miRNA expression might contribute enhanced progressive and invasive characteristics, such as epithelial-mesenchymal transition (EMT), of malignant tumors by regulating the translation of growth factor-induced functional molecules. There are a growing number of reports that describe the translational regulation of growth factors, their receptors, and intracellular signaling molecules by miRNAs in various tumors. However, less of the reports describe the regulation of miRNA expression by a growth factor itself. In this article, we review the relation of tumor development and progression by growth factors with miRNA expression, especially the regulation of miRNA expression by growth factors, and focus on the cooperative interactions of miRNAs, their mRNA targets, and growth factor signaling, in the context of tumor progression.

Keywords

microRNA (miRNA) growth factor Hepatocyte growth factor (HGF) Epidermal growth factor (EGF) Post-transcriptional regulation 

Notes

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. 1.
    Witsch E, Sela M, Yarden Y. Roles for growth factors in cancer progression. Physiology (Bethesda). 2010;25:85–101.  https://doi.org/10.1152/physiol.00045.2009.Google Scholar
  2. 2.
    Yarden Y, Ullrich A. Growth factor receptor tyrosine kinases. Annu Rev Biochem. 1988;57:443–78.PubMedCrossRefGoogle Scholar
  3. 3.
    Moustakas A, Heldin CH. Signaling networks guiding epithelial-mesenchymal transitions during embryogenesis and cancer progression. Cancer Sci. 2007;98:1512–20.PubMedCrossRefGoogle Scholar
  4. 4.
    Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281–97.PubMedCrossRefGoogle Scholar
  5. 5.
    Calin GA, Groce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006;6:857–66.PubMedCrossRefGoogle Scholar
  6. 6.
    Kedmi M, Sas-Chen A, Yarden Y. MicroRNAs and growth factors: an alliance propelling tumor progression. J Clin Med. 2015;4:1578–99.  https://doi.org/10.3390/jcm4081578.PubMedPubMedCentralCrossRefGoogle Scholar
  7. 7.
    Kimura S, Naganuma S, Susuki D, et al. Expression of microRNAs in squamous cell carcinoma of human head and neck and the esophagus: miR-205 and miR-21 are specific markers for HNSCC and ESCC. Oncol Rep. 2010;23:1625–33.PubMedGoogle Scholar
  8. 8.
    Futreal PA, Coin L, Marshall M, et al. A census of human cancer genes. Nat Rev Cancer. 2004;4:177–83.  https://doi.org/10.1038/nrc1299.PubMedPubMedCentralCrossRefGoogle Scholar
  9. 9.
    Sporn MB, Todaro GJ. Autocrine secretion and malignant transformation of cells. N Engl J Med. 1980;303:878–80.PubMedCrossRefGoogle Scholar
  10. 10.
    Di Fiore PP, Pierce JH, Kraus MH, et al. erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science. 1987;237:178–82.PubMedCrossRefGoogle Scholar
  11. 11.
    Huang HS, Nagane M, Klingbeil CK, et al. The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling. J Biol Chem. 1997;272:2927–35.PubMedCrossRefGoogle Scholar
  12. 12.
    Shrestha G, MacNeil SM, McQuerry JA, et al. The value of genomics in dissecting the RAS-network and in guiding therapeutics for RAS-driven cancers. Semin Cell Dev Biol. 2016;58:108–17.  https://doi.org/10.1016/j.semcdb.2016.06.012.PubMedCrossRefGoogle Scholar
  13. 13.
    Chen WB, Lenschow W, Tiede K, et al. Smad4/DPC4-dependent regulation of biglycan gene expression by transforming growth factor-beta in pancreatic tumor cells. J Biol Chem. 2002;277:36118–28.PubMedCrossRefGoogle Scholar
  14. 14.
    Yilmaz M, Christofori G. EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev. 2009;28:15–33.PubMedCrossRefGoogle Scholar
  15. 15.
    Yeung KT, Yang J. Epithelial-mesenchymal transition in tumor metastasis. Mol Oncol. 2017;11:28–39.  https://doi.org/10.1002/1878-0261.12017.PubMedCrossRefGoogle Scholar
  16. 16.
    Stetler-Stevenson WG. Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention. J Clin Invest. 1999;103:1237–41.PubMedPubMedCentralCrossRefGoogle Scholar
  17. 17.
    Werb Z. ECM and cell surface proteolysis: regulating cellular ecology. Cell. 1997;91:439–42.PubMedCrossRefGoogle Scholar
  18. 18.
    Jiang WG, Sanders AJ, Katoh M, et al. Tissue invasion and metastasis: molecular, biological and clinical perspectives. Semin Cancer Biol. 2015;35(Suppl):S244–75.  https://doi.org/10.1016/j.semcancer.2015.03.008.PubMedCrossRefGoogle Scholar
  19. 19.
    Rak J, Filmus J, Finkenzeller G, et al. Oncogenes as inducers of tumor angiogenesis. Cancer Metastasis Rev. 1995;14:263–77.PubMedCrossRefGoogle Scholar
  20. 20.
    Bikfalvi A. Significance of angiogenesis in tumour progression and metastasis. Eur J Cancer. 1995;31A:1101–4.PubMedCrossRefGoogle Scholar
  21. 21.
    Lin Z, Zhang Q, Luo W. Angiogenesis inhibitors as therapeutic agents in cancer: challenges and future directions. Eur J Pharmacol. 2016;793:76–81.  https://doi.org/10.1016/j.ejphar.2016.10.039.PubMedCrossRefGoogle Scholar
  22. 22.
    Ghorai A, Ghosh U. miRNA gene counts in chromosomes vary widely in a species and biogenesis of miRNA largely depends on transcription or post-transcriptional processing of coding genes. Front Genet. 2014;5:100.  https://doi.org/10.3389/fgene.2014.00100.PubMedPubMedCentralCrossRefGoogle Scholar
  23. 23.
    Donzelli S, Cioce M, Muti P, et al. MicroRNAs: non-coding fine tuners of receptor tyrosine kinase signalling in cancer. Semin Cell Dev Biol. 2016;50:133–42.  https://doi.org/10.1016/j.semcdb.2015.12.020.PubMedCrossRefGoogle Scholar
  24. 24.
    Ivey KN, Srivastava D. microRNAs as developmental regulators. Cold Spring Harb Perspect Biol. 2015;7:a008144.  https://doi.org/10.1101/cshperspect.a008144.PubMedPubMedCentralCrossRefGoogle Scholar
  25. 25.
    Davis-Dusenbery BN, Hata A. Mechanisms of control of microRNA biogenesis. J Biochem. 2010;148:381–92.  https://doi.org/10.1093/jb/mvq096.PubMedPubMedCentralGoogle Scholar
  26. 26.
    Lin S, Gregory RI. MicroRNA biogenesis pathways in cancer. Nat Rev Cancer. 2015;15:321–33.  https://doi.org/10.1038/nrc3932.PubMedPubMedCentralCrossRefGoogle Scholar
  27. 27.
    Blahna MT, Hata A. Regulation of miRNA biogenesis as an integrated component of growth factor signaling. Curr Opin Cell Biol. 2013;25:233–40.  https://doi.org/10.1016/j.ceb.2012.12.005.PubMedPubMedCentralCrossRefGoogle Scholar
  28. 28.
    Gurtan AM, Sharp PA. The role of miRNAs in regulating gene expression networks. J Mol Biol. 2013;425:3582–600.  https://doi.org/10.1016/j.jmb.2013.03.007.PubMedPubMedCentralCrossRefGoogle Scholar
  29. 29.
    Avraham R, Yarden Y. Regulation of signalling by microRNAs. Biochem Soc Trans. 2012;40:26–30.  https://doi.org/10.1042/BST20110623.PubMedPubMedCentralCrossRefGoogle Scholar
  30. 30.
    Shi XB, Tepper CG, deVere White RW. Cancerous miRNAs and their regulation. Cell Cycle. 2008;7:1529–38.PubMedCrossRefGoogle Scholar
  31. 31.
    Pichler M, Calin GA. MicroRNAs in cancer: from developmental genes in worms to their clinical application in patients. Br J Cancer. 2015;113:569–73.  https://doi.org/10.1038/bjc.2015.253.PubMedPubMedCentralCrossRefGoogle Scholar
  32. 32.
    Calin GA, Dumitru CD, Shimizu M, et al. Frequent deletions and down-regulation of micro-RNA genes mir15 and mir16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2002;99:15524–9.PubMedPubMedCentralCrossRefGoogle Scholar
  33. 33.
    Di Leva G, Croce CM. Roles of small RNAs in tumor formation. Trends Mol Med. 2010;16:257–67.PubMedPubMedCentralCrossRefGoogle Scholar
  34. 34.
    Mendell JT, Olson EN. MicroRNAs in stress signaling and human disease. Cell. 2012;148:1172–87.PubMedPubMedCentralCrossRefGoogle Scholar
  35. 35.
    He L, Thomson JM, Hemann MT, et al. A microRNA polycistron as a potential human oncogene. Nature. 2005;435:828–33.PubMedPubMedCentralCrossRefGoogle Scholar
  36. 36.
    Kim HH, Kuwano Y, Srikantan S, et al. HuR recruits let-7/RISC to repress c-Myc expression. Genes Dev. 2009;23:1743–8.  https://doi.org/10.1101/gad.1812509.PubMedPubMedCentralCrossRefGoogle Scholar
  37. 37.
    Johnson SM, Grosshans H, Shingara J, et al. RAS is regulated by the let-7 microRNA family. Cell. 2005;120:635–47.PubMedCrossRefGoogle Scholar
  38. 38.
    Kumar MS, Erkeland SJ, Pester RE, et al. Suppression of non-small cell lung tumor development by the let-7 microRNA family. Proc Natl Acad Sci U S A. 2008;105:3903–8.  https://doi.org/10.1073/pnas.0712321105.PubMedPubMedCentralCrossRefGoogle Scholar
  39. 39.
    Svoronos AA, Engelman DM, Slack FJ. OncomiR or tumor suppressor? The duplicity of MicroRNAs in cancer. Cancer Res. 2016;76:3666–70.  https://doi.org/10.1158/0008-5472.CAN-16-0359.PubMedPubMedCentralCrossRefGoogle Scholar
  40. 40.
    Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature. 2005;435:834–8.PubMedCrossRefGoogle Scholar
  41. 41.
    arube Y, Tanaka H, Osada H, et al. Reduced expression of Dicer associated with poor prognosis in lung cancer patients. Cancer Sci. 2005;96:111–5.CrossRefGoogle Scholar
  42. 42.
    Lin RJ, Lin YC, Chen J, et al. MicroRNA signature and expression of Dicer and Drosha can predict prognosis and delineate risk groups in neuroblastoma. Cancer Res. 2010;70:7841–50.  https://doi.org/10.1158/0008-5472.CAN-10-0970.PubMedPubMedCentralCrossRefGoogle Scholar
  43. 43.
    Merritt WM, Lin YG, Han LY, et al. Dicer, Drosha, and outcomes in patients with ovarian cancer. N Engl J Med. 2008;359:2641–50.  https://doi.org/10.1056/NEJMoa0803785.PubMedPubMedCentralCrossRefGoogle Scholar
  44. 44.
    Kumar MS, Lu J, Mercer KL, et al. Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat Genet. 2007;39:673–7.PubMedCrossRefGoogle Scholar
  45. 45.
    Hill DA, Ivanovich J, Priest JR, et al. DICER1 mutations in familial pleuropulmonary blastoma. Science. 2009;325:965.  https://doi.org/10.1126/science.1174334.PubMedPubMedCentralCrossRefGoogle Scholar
  46. 46.
    Foulkes WD, Priest JR, Duchaine TF. DICER1: mutations, microRNAs and mechanisms. Nat Rev Cancer. 2014;14:662–72.  https://doi.org/10.1038/nrc3802.PubMedCrossRefGoogle Scholar
  47. 47.
    Rakheja D, Chen KS, Liu Y, et al. Somatic mutations in DROSHA and DICER1 impair microRNA biogenesis through distinct mechanisms in Wilms tumours. Nat Commun. 2014;2:4802.  https://doi.org/10.1038/ncomms5802.PubMedCrossRefGoogle Scholar
  48. 48.
    Torrezan GT, Ferreira EN, Nakahata AM, et al. Recurrent somatic mutation in DROSHA induces microRNA profile changes in Wilms tumour. Nat Commun. 2014;5:4039.  https://doi.org/10.1038/ncomms5039.PubMedPubMedCentralCrossRefGoogle Scholar
  49. 49.
    Wegert J, Ishaque N, Vardapour R, et al. Mutations in the SIX1/2 pathway and the DROSHA/DGCR8 miRNA microprocessor complex underlie high-risk blastemal type Wilms tumors. Cancer Cell. 2015;27:298–311.  https://doi.org/10.1016/j.ccell.2015.01.002.PubMedCrossRefGoogle Scholar
  50. 50.
    Walz AL, Ooms A, Gadd S, et al. Recurrent DGCR8, DROSHA, and SIX homeodomain mutations in favorable histology Wilms tumors. Cancer Cell. 2015;27:286–97.  https://doi.org/10.1016/j.ccell.2015.01.003.PubMedPubMedCentralCrossRefGoogle Scholar
  51. 51.
    Webster RJ, Giles KM, Price KJ. Regulation of epidermal growth factor receptor signaling in human cancer cells by microRNA-7. J Biol Chem. 2009;284:5731–41.  https://doi.org/10.1074/jbc.M804280200.PubMedCrossRefGoogle Scholar
  52. 52.
    Kefas B, Godlewski J, Comeau L, et al. MicroRNA-7 inhibits the epidermal growth factor receptor and the akt pathway and is down-regulated in glioblastoma. Cancer Res. 2008;68:3566–72.  https://doi.org/10.1158/0008-5472.CAN-07-6639.PubMedCrossRefGoogle Scholar
  53. 53.
    Weiss GJ, Bemis LT, Nakajima E, et al. EGFR regulation by microRNA in lung cancer: correlation with clinical response and survival to gefitinib and EGFR expression in cell lines. Ann Oncol. 2008;19:1053–9.  https://doi.org/10.1093/annonc/mdn006.PubMedCrossRefGoogle Scholar
  54. 54.
    Chiyomaru T, Seki N, Inoguchi S, et al. Dual regulation of receptor tyrosine kinase genes EGFR and c-met by the tumor-suppressive microRNA-23b/27b cluster in bladder cancer. Int J Oncol. 2015;46:487–96.  https://doi.org/10.3892/ijo.2014.2752.PubMedCrossRefGoogle Scholar
  55. 55.
    Wang LK, Hsiao TH, Hong TM, et al. MicroRNA-133a suppresses multiple oncogenic membrane receptors and cell invasion in non-small cell lung carcinoma. PLoS One. 2014;9:e96765.  https://doi.org/10.1371/journal.pone.0096765.PubMedPubMedCentralCrossRefGoogle Scholar
  56. 56.
    Cui W, Zhang S, Shan C, et al. MicroRNA-133a regulates the cell cycle and proliferation of breast cancer cells by targeting epidermal growth factor receptor through the EGFR/AKT signaling pathway. FEBS J. 2013;280:3962–74.  https://doi.org/10.1111/febs.12398.PubMedCrossRefGoogle Scholar
  57. 57.
    Liu L, Shao X, Gao W, et al. MicroRNA-133b inhibits the growth of non-small-cell lung cancer by targeting the epidermal growth factor receptor. FEBS J. 2012;279:3800–12.  https://doi.org/10.1111/j.1742-4658.2012.08741.x.PubMedCrossRefGoogle Scholar
  58. 58.
    Kumaraswamy E, Wendt KL, Augustine LA, et al. BRCA1 regulation of epidermal growth factor receptor (EGFR) expression in human breast cancer cells involves microRNA-146a and is critical for its tumor suppressor function. Oncogene. 2014;34:4333–46.  https://doi.org/10.1038/onc.2014.363.PubMedPubMedCentralCrossRefGoogle Scholar
  59. 59.
    Katakowski M, Zheng X, Jiang F, et al. Mir-146b-5p suppresses EGFR expression and reduces in vitro migration and invasion of glioma. Cancer Invest. 2010;28:1024–30.  https://doi.org/10.3109/07357907.2010.512596.PubMedPubMedCentralCrossRefGoogle Scholar
  60. 60.
    Rao SA, Arimappamagan A, Pandey P, et al. Mir-219-5p inhibits receptor tyrosine kinase pathway by targeting EGFR in glioblastoma. PLoS One. 2013;8:e63164.  https://doi.org/10.1371/journal.pone.0063164.PubMedPubMedCentralCrossRefGoogle Scholar
  61. 61.
    Wang L, Yao J, Shi X, et al. MicroRNA-302b suppresses cell proliferation by targeting EGFR in human hepatocellular carcinoma SMMC-7721 cells. BMC Cancer. 2013;13:448.  https://doi.org/10.1186/1471-2407-13-448.PubMedPubMedCentralCrossRefGoogle Scholar
  62. 62.
    Zhang Y, Schiff D, Park D, et al. MicroRNA-608 and microRNA-34a regulate chordoma malignancy by targeting EGFR, Bcl-xL and MET. PLoS One. 2014;9:e91546.  https://doi.org/10.1371/journal.pone.0091546.PubMedPubMedCentralCrossRefGoogle Scholar
  63. 63.
    Uhlmann S, Mannsperger H, Zhang JD, et al. Global microRNA level regulation of EGFR-driven cell-cycle protein network in breast cancer. Mol Syst Biol. 2012;8:570.  https://doi.org/10.1038/msb.2011.100.PubMedPubMedCentralCrossRefGoogle Scholar
  64. 64.
    Pagliuca A, Valvo C, Fabrizi E, et al. Analysis of the combined action of mir-143 and mir-145 on oncogenic pathways in colorectal cancer cells reveals a coordinate program of gene repression. Oncogene. 2013;32:4806–13.  https://doi.org/10.1038/onc.2012.495.PubMedCrossRefGoogle Scholar
  65. 65.
    Pekow JR, Dougherty U, Mustafi R, et al. Mir-143 and mir-145 are downregulated in ulcerative colitis: putative regulators of inflammation and protooncogenes. Inflamm Bowel Dis. 2012;18:94–100.  https://doi.org/10.1002/ibd.21742.PubMedCrossRefGoogle Scholar
  66. 66.
    Xu B, Niu X, Zhang X, et al. Mir-143 decreases prostate cancer cells proliferation and migration and enhances their sensitivity to docetaxel through suppression of kras. Mol Cell Biochem. 2011;350:207–13.  https://doi.org/10.1007/s11010-010-0700-6.PubMedCrossRefGoogle Scholar
  67. 67.
    Wu X, Bhayani MK, Dodge CT, et al. Coordinated targeting of the EGFR signaling axis by microrna-27a*. Oncotarget. 2013;4:1388–98.PubMedPubMedCentralGoogle Scholar
  68. 68.
    Leivonen SK, Sahlberg KK, Makela R, et al. High-throughput screens identify microRNAs essential for HER2 positive breast cancer cell growth. Mol Oncol. 2014;8:93–104.  https://doi.org/10.1016/j.molonc.2013.10.001.PubMedCrossRefGoogle Scholar
  69. 69.
    Giles KM, Barker A, Zhang PM, et al. MicroRNA regulation of growth factor receptor signaling in human cancer cells. Methods Mol Biol. 2011;676:147–63.PubMedCrossRefGoogle Scholar
  70. 70.
    Epis MR, Giles KM, Barker A, et al. Mir-331-3p regulates ERBB2 expression and androgen receptor signaling in prostate cancer. J Biol Chem. 2009;284:24696–704.  https://doi.org/10.1074/jbc.M109.030098.PubMedPubMedCentralCrossRefGoogle Scholar
  71. 71.
    Bischoff A, Bayerlova M, Strotbek M, et al. A global microRNA screen identifies regulators of the ERBB receptor signaling network. Cell Commun Signal. 2015;13:5.  https://doi.org/10.1186/s12964-015-0084-z.PubMedPubMedCentralCrossRefGoogle Scholar
  72. 72.
    Scott GK, Goga A, Bhaumik D, et al. Coordinate suppression of ERBB2 and ERBB3 by enforced expression of microRNA mir-125a or mir-125b. J Biol Chem. 2007;282:1479–86.  https://doi.org/10.1074/jbc.M609383200.PubMedCrossRefGoogle Scholar
  73. 73.
    Liang H, Liu M, Yan X, et al. Mir-193a-3p functions as a tumor suppressor in lung cancer by down-regulating ERBB4. J Biol Chem. 2015;290:926–40.  https://doi.org/10.1074/jbc.M114.621409.PubMedCrossRefGoogle Scholar
  74. 74.
    Yu T, Li J, Yan M, et al. MicroRNA-193a-3p and -5p suppress the metastasis of human non-small-cell lung cancer by downregulating the ERBB4/PIK3R3/mTOR/S6K2 signaling pathway. Oncogene. 2015;34:413–23.  https://doi.org/10.1038/onc.2013.574.PubMedCrossRefGoogle Scholar
  75. 75.
    Zhang M, Yang Q, Zhang L, et al. Mir-302b is a potential molecular marker of esophageal squamous cell carcinoma and functions as a tumor suppressor by targeting ERBB4. J Exp Clin Cancer Res. 2014;33:10.  https://doi.org/10.1186/1756-9966-33-10.PubMedPubMedCentralCrossRefGoogle Scholar
  76. 76.
    Guo L, Zhang Y, Zhang L, et al. MicroRNAs, TGF-β signaling, and the inflammatory microenvironment in cancer. Tumour Biol. 2016;37:115–25.  https://doi.org/10.1007/s13277-015-4374-2.PubMedCrossRefGoogle Scholar
  77. 77.
    Butz H, Rácz K, Hunyady L, et al. Crosstalk between TGF-β signaling and the microRNA machinery. Trends Pharmacol Sci. 2012;33:382–93.  https://doi.org/10.1016/j.tips.2012.04.003.PubMedCrossRefGoogle Scholar
  78. 78.
    Sivadas VP, Kannan S. The microRNA networks of TGF-β signaling in cancer. Tumour Biol. 2014;35:2857–69.  https://doi.org/10.1007/s13277-013-1481-9.PubMedCrossRefGoogle Scholar
  79. 79.
    Martin J, Jenkins RH, Bennagi R, et al. Post-transcriptional regulation of transforming growth factor beta-1 by microRNA-744. PLoS One. 2011;6:e25044.  https://doi.org/10.1371/journal.pone.0025044.PubMedPubMedCentralCrossRefGoogle Scholar
  80. 80.
    Dogar AM, Towbin H, Hall J. Suppression of latent transforming growth factor (TGF)-β1 restores growth inhibitory TGF-β signaling through microRNAs. J Biol Chem. 2011;286:16447–58.  https://doi.org/10.1074/jbc.M110.208652.PubMedPubMedCentralCrossRefGoogle Scholar
  81. 81.
    Dogar AM, Semplicio G, Guennewig B, et al. Multiple microRNAs derived from chemically synthesized precursors regulate thrombospondin 1 expression. Nucleic Acid Ther. 2014;24:149–59.  https://doi.org/10.1089/nat.2013.0467.PubMedPubMedCentralCrossRefGoogle Scholar
  82. 82.
    Braun J, Hoang-Vu C, Dralle H, et al. Downregulation of microRNAs directs the EMT and invasive potential of anaplastic thyroid carcinomas. Oncogene. 2010;29:4237–44.  https://doi.org/10.1038/onc.2010.169.PubMedCrossRefGoogle Scholar
  83. 83.
    Masri S, Liu Z, Phung S, et al. The role of microRNA-128a in regulating TGF-beta signaling in letrozole-resistant breast cancer cells. Breast Cancer Res Treat. 2010;124:89–99.  https://doi.org/10.1007/s10549-009-0716-3.PubMedPubMedCentralCrossRefGoogle Scholar
  84. 84.
    Li S, Zhang H, Wang X. Direct targeting of HGF by miR-16 regulates proliferation and migration in gastric cancer. Tumour Biol. 2016;37:15175–83.PubMedCrossRefGoogle Scholar
  85. 85.
    Chen QY, Jiao DM, YQ W. MiR-206 inhibits HGF-induced epithelial-mesenchymal transition and angiogenesis in non-small cell lung cancer via c-met/PI3k/Akt/mTOR pathway. Oncotarget. 2016;7:18247–61.  10.18632/oncotarget.7570.PubMedPubMedCentralGoogle Scholar
  86. 86.
    Yang X, Zhang XF, Lu X. MicroRNA-26a suppresses angiogenesis in human hepatocellular carcinoma by targeting hepatocyte growth factor-cMet pathway. Hepatology. 2014;59:1874–85.  https://doi.org/10.1002/hep.26941.PubMedCrossRefGoogle Scholar
  87. 87.
    Tan S, Li R, Ding K. miR-198 inhibits migration and invasion of hepatocellular carcinoma cells by targeting the HGF/c-MET pathway. FEBS Lett. 2011;585:2229–34.  https://doi.org/10.1016/j.febslet.2011.05.042.PubMedCrossRefGoogle Scholar
  88. 88.
    Rokavee M, Li H, Jiang L, et al. The p53/miR-34 axis in development and disease. J Mol Cell Biol. 2014;6:214–30.CrossRefGoogle Scholar
  89. 89.
    Brighenti M. MicroRNA and MET in lung cancer. Ann Transl Med. 2014;3:68.  https://doi.org/10.3978/j.issn.2305-5839.2015.01.26.Google Scholar
  90. 90.
    Jung HJ, Suh Y. Regulation of IGF-1 signaling by microRNAs. Front Genet. 2015;5:472.  https://doi.org/10.3389/fgene.2014.00472.PubMedPubMedCentralCrossRefGoogle Scholar
  91. 91.
    Correia AC, Moonen JR, Brinker MG. FGF2 inhibits endothelial-mesenchymal transition through microRNA-20a-mediated repression of canonical TGF-β signaling. J Cell Sci. 2016;129:569–79.  https://doi.org/10.1242/jcs.176248.PubMedCrossRefGoogle Scholar
  92. 92.
    Xiao J, Bei Y, Liu J. miR-212 downregulation contributes to the protective effect of exercise against non-alcoholic fatty liver via targeting FGF-21. J Cell Mol Med. 2016;20:204–16.  https://doi.org/10.1111/jcmm.12733.PubMedCrossRefGoogle Scholar
  93. 93.
    Chen XY, Li GM, Dong Q. MiR-577 inhibits pancreatic β-cell function and survival by targeting fibroblast growth factor 21 (FGF-21) in pediatric diabetes. Genet Mol Res. 2015;14:15462–70.  https://doi.org/10.4238/2015.November.30.24.PubMedCrossRefGoogle Scholar
  94. 94.
    Wang L, Ma L, Fan H. MicroRNA-9 regulates cardiac fibrosis by targeting PDGFR-β in rats. J Physiol Biochem. 2016;72:213–23.  https://doi.org/10.1007/s13105-016-0471-y.PubMedCrossRefGoogle Scholar
  95. 95.
    Wang W, Zhang E, Lin C. MicroRNAs in tumor angiogenesis. Life Sci. 2015;136:28–35.PubMedCrossRefGoogle Scholar
  96. 96.
    Landskroner-Eiger S, Moneke I, Sessa WC. miRNAs as modulators of angiogenesis. Cold Spring Harb Perspect Med. 2013;3:a006643.PubMedPubMedCentralCrossRefGoogle Scholar
  97. 97.
    Ohnishi T, Daikuhara Y. Hepatocyte growth factor/scatter factor in development, inflammation and carcinogenesis: its expression and role in oral tissues. Arch Oral Biol. 2003;48:797–804.PubMedCrossRefGoogle Scholar
  98. 98.
    Uchida D, Kawamata H, Omotehara F, et al. Role of HGF/c-MET system in invasion and metastasis of oral squamous cell carcinoma cells in vitro and its clinical significance. Int J Cancer. 2001;93:489–96.PubMedCrossRefGoogle Scholar
  99. 99.
    Knowles LM, Stabile LP, Egloff AM, et al. HGF and c-met participate in paracrine tumorigenic pathways in head and neck squamous cell cancer. Clin Cancer Res. 2009;15:3740–50.PubMedPubMedCentralCrossRefGoogle Scholar
  100. 100.
    Matsumoto K, Nakamura T. Hepatocyte growth factor and the met system as a mediator of tumor-stromal interactions. Int J Cancer. 2006;119:477–83.PubMedCrossRefGoogle Scholar
  101. 101.
    Ding W, You H, Dang H, et al. Epithelial-to-mesenchymal transition of murine liver tumor cells promotes invasion. Hepatology. 2010;52:945–53.PubMedPubMedCentralCrossRefGoogle Scholar
  102. 102.
    Morello S, Olivero M, Aimetti M, et al. MET receptor is overexpressed but not mutated in oral squamous cell carcinoma. J Cell Physiol. 2001;189:285–90.PubMedCrossRefGoogle Scholar
  103. 103.
    Ren Y, Cao B, Law S et al (2005) Hepatocyte growth factor promotes cancer cell migration and angiogenic factors expression: a prognostic marker of human esophageal squamous cell carcinomas. Clin Cancer Res11:6190–6197.Google Scholar
  104. 104.
    Dong G, Chen Z, Li ZY, et al. Hepatocyte growth factor/scatter factor-induced activation of MEK and PI3K signal pathways contributes to expression of proangiogenic cytokines interleukin-8 and vascular endothelial growth factor in head and neck squamous cell carcinoma. Cancer Res. 2001;61:5911–8.PubMedGoogle Scholar
  105. 105.
    Hanzawa M, Shindoh M, Higashino F, et al. Hepatocyte growth factor upregulates E1AF that induces oral squamous cell carcinoma cell invasion by activating matrix metalloproteinase genes. Carcinogenesis. 2000;21:1079–85.PubMedCrossRefGoogle Scholar
  106. 106.
    Susuki D, Kimura S, Naganuma S, et al. Regulation of microRNA expression by hepatocyte growth factor in head and neck squamous cell carcinoma. Cancer Sci. 2011;102:2164–71.  https://doi.org/10.1111/j.1349-7006.2011.02096.x.PubMedCrossRefGoogle Scholar
  107. 107.
    Gregory PA, Bert AG, Paterson EL, et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol. 2008;10:593–601.PubMedCrossRefGoogle Scholar
  108. 108.
    Bracken CP, Gregory PA, Kolesnikoff N, et al. A double-negative feedback loop between ZEB1-SIP1 and the microRNA-200 family regulates epithelial-mesenchymal transition. Cancer Res. 2008;68:7846–54.PubMedCrossRefGoogle Scholar
  109. 109.
    Wang Y, Rathinam R, Walch A, et al. ST14(suppression of tumorigenicity 14) gene is a target for miR-27b, and the inhibitory effect of ST14 on cell growth is independent of miR-27b regulation. J Biol Chem. 2009;284:23094–106.PubMedPubMedCentralCrossRefGoogle Scholar
  110. 110.
    Santin AD, Cane S, Bellone S, et al. The novel serine proteas tumor-associated differentially expressed gene-15 (matriptase/MT-SP1) is highly overexpressed in cervical carcinoma. Cancer. 2003;98:1898–904.PubMedCrossRefGoogle Scholar
  111. 111.
    Lee SL, Huang PY, Roller P, et al. Matriptase/epithin participates in mammary epithelial cell growth and morphogenesis through HGF activation. Mech Dev. 2010;127:82–95.PubMedCrossRefGoogle Scholar
  112. 112.
    Ding KF, Sun LF, Ge WT, et al. Effect of SNC19/ST14 gene expression on invasion of colorectal cancer cells. World J Gastroenterol. 2005;11:5651–4.PubMedPubMedCentralCrossRefGoogle Scholar
  113. 113.
    List K, Szabo R, Molinolo A, et al. Delineation of matriptase protein expression by enzymatic gene trapping suggests diverging roles in barrier function, hair formation, and squamous cell carcinogenesis. Am J Pathol. 2006;168:1513–25.PubMedPubMedCentralCrossRefGoogle Scholar
  114. 114.
    Zhang B, Pan X, Cobb GP, et al. MicroRNAs as oncogenes and tumor suppressors. Dev Biol. 2006;289:3–16.PubMedCrossRefGoogle Scholar
  115. 115.
    Esquela-Kerscher A, Slack FJ. Oncomirs―microRNAs with a role in cancer. Nat Rev Cancer. 2006;6:259–69.PubMedCrossRefGoogle Scholar
  116. 116.
    Tamaru Y, Hayashizaki Y. Cancer research with non-coding RNA. Cancer Sci. 2006;97:1285–90.CrossRefGoogle Scholar
  117. 117.
    Hoa M, Davis SL, Ames SJ, et al. Amplification of wild-type K-ras promotes growth of head and neck squamous cell carcinoma. Cancer Res. 2002;62:7154–6.PubMedGoogle Scholar
  118. 118.
    Weidhaas JB, Babar I, Nallur SM, et al. MicroRNA as potential agents to alter resistance to cytotoxic anticancer therapy. Cancer Res. 2007;67:11111–6.PubMedCrossRefGoogle Scholar
  119. 119.
    Cimmino A, Calin GA, Fabbri M, et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A. 2005;102:13944–9.PubMedPubMedCentralCrossRefGoogle Scholar
  120. 120.
    Gao P, Tchernyshyov I, Chang TC, et al. C-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature. 2009;458:762–5.PubMedPubMedCentralCrossRefGoogle Scholar
  121. 121.
    Mouillet JF, Chu T, Nelson DM, et al. MiR-205 silences MED1 in hypoxic primary human trophoblasts. FASEB J. 2010;24:2030–9.PubMedPubMedCentralCrossRefGoogle Scholar
  122. 122.
    Mertens-Talcott SU, Chintharlapalli S, Li X, et al. The oncogenic microRNA-27a targets genes that regulate specificity protein transcription factors and the G2-M checkpoint in MDA-MB-231 breast cancer cells. Cancer Res. 2007;67:11001–11.PubMedCrossRefGoogle Scholar
  123. 123.
    Zhang H, Li M, Han Y, et al. Down-regulation of miR-27a might reverse multidrug resistance of esophageal squamous cell carcinoma. Dig Dis Sci. 2010;55:2545–51.PubMedCrossRefGoogle Scholar
  124. 124.
    Iorio MV, Casalini P, Piovan C, et al. microRNA-205 regulates HER3 in human breast cancer. Cancer Res. 2009;69:2195–200.PubMedCrossRefGoogle Scholar
  125. 125.
    Childs G, Fazzari M, Kung G, et al. Low-level expression of microRNAs let-7d and miR-205 are prognostic markers of head and neck squamous cell carcinoma. Am J Pathol. 2009;174:736–45.PubMedPubMedCentralCrossRefGoogle Scholar
  126. 126.
    Zidar N, Boštjančič E, Gale N, et al. Down-regulation of microRNAs of the miR-200 family and miR-205, and an altered expression of classic and desmosomal cadherins in spindle cell carcinoma of the head and neck-hallmark of epithelial-mesenchymal transition. Hum Pathol. 2011;42:482–8.  https://doi.org/10.1016/j.humpath.2010.07.020.PubMedCrossRefGoogle Scholar
  127. 127.
    Avraham R, Sas-Chen A, Manor O, et al. EGF decreases the abundance of microRNAs that restrain oncogenic transcription factors. Sci Signal. 2010;3:ra43.  https://doi.org/10.1126/scisignal.2000876.PubMedCrossRefGoogle Scholar
  128. 128.
    Kedmi M, Ben-Chetrit N, Korner C et al (2015) EGF induces microRNAs that target suppressors of cell migration: Mir-15b targets MTSS1 in breast cancer. Sci Signal 8:ra29. doi:  https://doi.org/10.1126/scisignal.2005866.
  129. 129.
    Tarcic G, Avraham R, Pines G, et al. EGR1 and the ERK-ERF axis drive mammary cell migration in response to EGF. FASEB J. 2012;26:1582–92.  https://doi.org/10.1096/fj.11-194654.PubMedPubMedCentralCrossRefGoogle Scholar
  130. 130.
    Katz M, Amit I, Citri A, et al. A reciprocal tensin-3-cten switch mediates EGF-driven mammary cell migration. Nat Cell Biol. 2007;9:961–9.  https://doi.org/10.1038/ncb1622.PubMedCrossRefGoogle Scholar
  131. 131.
    Llorens F, Hummel M, Pantano L, et al. Microarray and deep sequencing cross-platform analysis of the mirrnome and isomir variation in response to epidermal growth factor. BMC Genomics. 2013;14:371.  https://doi.org/10.1186/1471-2164-14-371.PubMedPubMedCentralCrossRefGoogle Scholar
  132. 132.
    WC L, Kao SY, Yang CC, et al. EGF up-regulates mir-31 through the C/EBPbeta signal cascade in oral carcinoma. PLoS One. 2014;9:e108049.  https://doi.org/10.1371/journal.pone.0108.CrossRefGoogle Scholar
  133. 133.
    Ben-Chetrit N, Chetrit D, Russell R, et al. Synaptojanin 2 is a druggable mediator of metastasis and the gene is overexpressed and amplified in breast cancer. Sci Signal. 2015;8:ra7.  https://doi.org/10.1126/scisignal.2005537.PubMedCrossRefGoogle Scholar
  134. 134.
    Alanazi I, Hoffmann P, Adelson DL. MicroRNAs are part of the regulatory network that controls EGF induced apoptosis, including elements of the JAK/STAT pathway, in a431 cells. PLoS One. 2015;10:e0120337.  https://doi.org/10.1371/journal.pone.0120337.PubMedPubMedCentralCrossRefGoogle Scholar
  135. 135.
    Gomez GG, Volinia S, Croce CM, et al. Suppression of microRNA-9 by mutant EGFR signaling upregulates FOXp1 to enhance glioblastoma tumorigenicity. Cancer Res. 2014;74:1429–39.  https://doi.org/10.1158/0008-5472.CAN-13-2117.PubMedPubMedCentralCrossRefGoogle Scholar
  136. 136.
    Kao CJ, Martiniez A, Shi XB, et al. Mir-30 as a tumor suppressor connects EGF/src signal to ERG and EMT. Oncogene. 2014;33:2495–503.  https://doi.org/10.1038/onc.2013.200.PubMedCrossRefGoogle Scholar
  137. 137.
    Jazbutyte V, Thum T. MicroRNA-21: From cancer to cardiovascular disease. Curr Drug Targets. 2010;11:926–35.PubMedCrossRefGoogle Scholar
  138. 138.
    Asangani IA, Rasheed SAK, Nikolova DA, et al. MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor PDCD4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene. 2007;27:2128–36.PubMedCrossRefGoogle Scholar
  139. 139.
    Zhu S, Si M-L, Wu H, et al. MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1). J Biol Chem. 2007;282:14328–36.PubMedCrossRefGoogle Scholar
  140. 140.
    Meng F, Henson R, etal W–JH. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology. 2007;133:647–58.PubMedPubMedCentralCrossRefGoogle Scholar
  141. 141.
    Pan X, Wang Z-X, Wang R. MicroRNA-21: a novel therapeutic target in human cancer. Cancer Biol Ther. 2010;10:1224–32.PubMedCrossRefGoogle Scholar
  142. 142.
    Sampson VB, Rong NH, Han J, et al. MicroRNA let-7a down-regulates myc and reverts myc-induced growth in Burkitt lymphoma cells. Cancer Res. 2007;67:9762–70.PubMedCrossRefGoogle Scholar
  143. 143.
    Mayr C, Hemann MT, Bartel DP. Disrupting the pairing between let-7 and HMGA2 enhances oncogenic transformation. Science. 2007;315:1576–9.PubMedPubMedCentralCrossRefGoogle Scholar
  144. 144.
    Paroo Z, Ye X, Chen S, et al. Phosphorylation of the human microRNA-generating complex mediates MAPK/ERK signaling. Cell. 2009;139:112–21.PubMedPubMedCentralCrossRefGoogle Scholar
  145. 145.
    Blahna MT, Hata A. Smad-mediated regulation of microRNA biosynthesis. FEBS Lett. 2012;586:1906–12.  https://doi.org/10.1016/j.febslet.2012.01.041.PubMedPubMedCentralCrossRefGoogle Scholar
  146. 146.
    Hata A, Davis BN. Control of microRNA biogenesis by tgfbeta signaling pathway-a novel role of smads in the nucleus. Cytokine Growth Factor Rev. 2009;20:517–21.  https://doi.org/10.1016/j.cytogfr.2009.10.004.PubMedPubMedCentralCrossRefGoogle Scholar
  147. 147.
    Davis BN, Hilyard AC, etal LG. Smad proteins control DROSHA-mediated microRNA maturation. Nature. 2008;454:56–61.  https://doi.org/10.1038/nature07086.PubMedPubMedCentralCrossRefGoogle Scholar
  148. 148.
    Heldin CH, Moustakas A. Role of smads in TGF-beta signaling. Cell Tissue Res. 2011;347:21–36.  https://doi.org/10.1007/s00441-011-1190-x.PubMedCrossRefGoogle Scholar
  149. 149.
    Davis BN, Hilyard AC, Nguyen PH, et al. Smad proteins bind a conserved RNA sequence to promote microRNA maturation by drosha. Mol Cell. 2010;39:373–84.  https://doi.org/10.1016/j.molcel.2010.07.011.PubMedPubMedCentralCrossRefGoogle Scholar
  150. 150.
    Wang W, Li J, etal ZW. MicroRNA-21 and the clinical outcomes of various carcinomas: a systematic review and meta-analysis. BMC Cancer. 2014;14:819.  https://doi.org/10.1186/1471-2407-14-819.PubMedPubMedCentralCrossRefGoogle Scholar
  151. 151.
    Yu Y, Wang Y, Ren X, et al. Context-dependent bidirectional regulation of the muts homolog 2 by transforming growth factor beta contributes to chemoresistance in breast cancer cells. Mol Cancer Res. 2010;8:1633–42.  https://doi.org/10.1158/1541-7786.MCR-10-0362.PubMedPubMedCentralCrossRefGoogle Scholar
  152. 152.
    Wang B, Hsu SH, Majumder S, et al. TGF-beta-mediated upregulation of hepatic mir-181b promotes hepatocarcinogenesis by targeting TIMP3. Oncogene. 2010;29:1787–97.  https://doi.org/10.1038/onc.2009.468.PubMedCrossRefGoogle Scholar
  153. 153.
    Liu Y, Lai L, Chen Q, et al. MicroRNA-494 is required for the accumulation and functions of tumor-expanded myeloid-derived suppressor cells via targeting of PTEN. J Immunol. 2012;188:5500–10.  https://doi.org/10.4049/jimmunol.1103505.PubMedCrossRefGoogle Scholar
  154. 154.
    Ma L, Reinhardt F, Pan E, et al. Therapeutic silencing of mir-10b inhibits metastasis in a mouse mammary tumor model. Nat Biotechnol. 2010;28:341–7.  https://doi.org/10.1038/nbt.1618.PubMedPubMedCentralCrossRefGoogle Scholar
  155. 155.
    Ma L. Role of mir-10b in breast cancer metastasis. Breast Cancer Res. 2010;12:210.  https://doi.org/10.1186/bcr2720.PubMedPubMedCentralCrossRefGoogle Scholar
  156. 156.
    Cheng CM, Shiah SG, Huang CC, et al. Up-regulation of miR-455-5p by the TGF-β-SMAD signalling axis promotes the proliferation of oral squamous cancer cells by targeting UBE2B. J Pathol. 2016;240:38–49.  https://doi.org/10.1002/path.4752.PubMedCrossRefGoogle Scholar
  157. 157.
    Yang P, Li Q-J, Feng Y, et al. TGF-β-mir-34a-ccl22 signaling-induced Treg cell recruitment promotes venous metastases of HBV-positive hepatocellular carcinoma. Cancer Cell. 2012;22:291–303.  https://doi.org/10.1016/j.ccr.2012.07.023.PubMedPubMedCentralCrossRefGoogle Scholar
  158. 158.
    Xu M, Gu M, Zhang K, et al. Mir-203 inhibition of renal cancer cell proliferation, migration and invasion by targeting of FGF2. Diagn Pathol. 2015;10:24.  https://doi.org/10.1186/s13000-015-0255-7.PubMedPubMedCentralCrossRefGoogle Scholar
  159. 159.
    Ding X, Park SI, McCauley LK, et al. Signaling between transforming growth factor beta (TGF-β) and transcription factor SNAL2 represses expression of microRNA mir-203 to promote epithelial-mesenchymal transition and tumor metastasis. J Biol Chem. 2013;288:10241–53.  https://doi.org/10.1074/jbc.M112.443655.PubMedPubMedCentralCrossRefGoogle Scholar
  160. 160.
    Fils-Aime N, Dai M, Guo J, et al. MicroRNA-584 and the protein phosphatase and actin regulator 1 (PHACTR1), a new signaling route through which transforming growth factor-beta mediates the migration and actin dynamics of breast cancer cells. J Biol Chem. 2013;288:11807–23.  https://doi.org/10.1074/jbc.M112.430934.PubMedPubMedCentralCrossRefGoogle Scholar
  161. 161.
    Sun MM, Li JF, Guo LL, et al. TGFβ1 suppression of microRNA-450b-5p expression: a novel mechanism for blocking myogenic differentiation of rhabdomyosarcoma. Oncogene. 2014;33:2075–86.  https://doi.org/10.1038/onc.2013.165.PubMedCrossRefGoogle Scholar
  162. 162.
    Chen PY, Qin L, Barnes C, et al. FGF regulates TGF-β signaling and endothelial-to-mesenchymal transition via control of let-7 miRNA expression. Cell Rep. 2012;2:1684–96.  https://doi.org/10.1016/j.celrep.2012.10.021.PubMedPubMedCentralCrossRefGoogle Scholar
  163. 163.
    Lee JY, Yun M, Paik JS, et al. PDGF-BB enhances the proliferation of cells in human orbital fibroblasts by suppressing PDCD4 expression via up-regulation of microRNA-21. Invest Ophthalmol Vis Sci. 2016;57:908–13.  https://doi.org/10.1167/iovs.15-18157.PubMedCrossRefGoogle Scholar
  164. 164.
    Kim S, Kang H. miR-15b induced by platelet-derived growth factor signaling is required for vascular smooth muscle cell proliferation. BMB Rep. 2013;46:550–4.PubMedPubMedCentralCrossRefGoogle Scholar
  165. 165.
    Cho WC, Chow AS, Au. S (2011) Mir-145 inhibits cell proliferation of human lung adenocarcinoma by targeting EGFR and NUDT1. RNA Biol 8:125–131. doi:  https://doi.org/10.4161/rna.8.1.14259.
  166. 166.
    Zhu H, Dougherty U, Robinson V, et al. EGFR signals downregulate tumor suppressors mir-143 and mir-145 in western diet-promoted murine colon cancer: role of G1 regulators. Mol Cancer Res. 2011;9:960–75.  https://doi.org/10.1158/1541-7786.MCR-10-0531.PubMedCrossRefGoogle Scholar
  167. 167.
    Guo YH, Zhang C, Shi J, et al. Abnormal activation of the EGFR signaling pathway mediates the downregulation of mir145 through the ERK1/2 in non-small cell lung cancer. Oncol Rep. 2014;31:1940–6.PubMedCrossRefGoogle Scholar
  168. 168.
    Zhang KL, Han L, Chen LY, et al. Blockage of a mir-21/EGFR regulatory feedback loop augments anti-EGFR therapy in glioblastomas. Cancer Lett. 2014;342:139–49.  https://doi.org/10.1016/j.canlet.2013.08.043.PubMedCrossRefGoogle Scholar
  169. 169.
    Seike M, Goto A, Okano T, et al. Mir-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers. Proc Natl Acad Sci U S A. 2009;106:12085–90.  https://doi.org/10.1073/pnas.0905234106.PubMedPubMedCentralCrossRefGoogle Scholar
  170. 170.
    Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747–52.  https://doi.org/10.1038/35021093.PubMedCrossRefGoogle Scholar
  171. 171.
    Volinia S, Calin GA, Liu CG, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A. 2006;103:2257–61.  https://doi.org/10.1073/pnas.0510565103.PubMedPubMedCentralCrossRefGoogle Scholar
  172. 172.
    Mitchell PS, Parkin RK, Kroh EM, et al. Circulating micrornas as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A. 2008;105:10513–8.  https://doi.org/10.1073/pnas.0804549105.PubMedPubMedCentralCrossRefGoogle Scholar
  173. 173.
    Chen X, Ba Y, Ma L, et al. Characterization of micrornas in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008;18:997–1006.  https://doi.org/10.1038/cr.2008.282.PubMedCrossRefGoogle Scholar
  174. 174.
    Takamizawa J, Konishi H, Yanagisawa K, et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res. 2004;64:3753–6.  https://doi.org/10.1158/0008-5472.CAN-04-0637.PubMedCrossRefGoogle Scholar
  175. 175.
    Nelson PT, Baldwin DA, Scearce LM, et al. Microarray-based, high-throughput gene expression profiling of micrornas. Nat Methods. 2004;1:155–61.  https://doi.org/10.1038/nmeth717.PubMedCrossRefGoogle Scholar
  176. 176.
    Lagos-Quintana M, Rauhut R, Yalcin A, et al. Identification of tissue-specific microRNAs from mouse. Curr Biol. 2002;12:735–9.  https://doi.org/10.1016/S0960-9822(02)00809-6.PubMedCrossRefGoogle Scholar
  177. 177.
    Rosenfeld N, Aharonov R, Meiri E, et al. MicroRNAs accurately identify cancer tissue origin. Nat Biotechnol. 2008;26:462–9.  https://doi.org/10.1038/nbt1392.PubMedCrossRefGoogle Scholar
  178. 178.
    Dvinge H, Git A, Graf S, et al. The shaping and functional consequences of the microRNA landscape in breast cancer. Nature. 2013;497:378–82.  https://doi.org/10.1038/nature12108.PubMedCrossRefGoogle Scholar
  179. 179.
    Blenkiron C, Goldstein LD, Thorne NP, et al. MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype. Genome Biol. 2007;8:R214.  https://doi.org/10.1186/gb-2007-8-10-r214.PubMedPubMedCentralCrossRefGoogle Scholar
  180. 180.
    Andorfer CA, Necela BM, Thompson EA, et al. MicroRNA signatures: clinical biomarkers for the diagnosis and treatment of breast cancer. Trends Mol Med. 2011;17:313–9.  https://doi.org/10.1016/j.molmed.2011.01.006.PubMedCrossRefGoogle Scholar
  181. 181.
    Enerly E, Steinfeld I, Kleivi K, et al. MiRNA-mRNA integrated analysis reveals roles for miRNAs in primary breast tumors. PLoS One. 2011;6:e16915.  https://doi.org/10.1371/journal.pone.0016915.PubMedPubMedCentralCrossRefGoogle Scholar
  182. 182.
    Yanaihara N, Caplen N, Bowman E, et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell. 2006;9:189–98.  https://doi.org/10.1016/j.ccr.2006.01.025.PubMedCrossRefGoogle Scholar
  183. 183.
    Hu Z, Chen X, Zhao Y, et al. Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. J Clin Oncol. 2010;28:1721–6.  https://doi.org/10.1200/JCO.2009.24.9342.PubMedCrossRefGoogle Scholar
  184. 184.
    Cho WC. MicroRNAs: potential biomarkers for cancer diagnosis, prognosis and targets for therapy. Int J Biochem Cell Biol. 2010;42:1273–81.  https://doi.org/10.1016/j.biocel.2009.12.014.PubMedCrossRefGoogle Scholar
  185. 185.
    Meiri E, Mueller WC, Rosenwald S, et al. A second-generation microRNA-based assay for diagnosing tumor tissue origin. Oncologist. 2012;17:801–12.  https://doi.org/10.1634/theoncologist.2011-0466.PubMedPubMedCentralCrossRefGoogle Scholar
  186. 186.
    Nair VS, Maeda LS, Ioannidis JP. Clinical outcome prediction by microRNAs in human cancer: a systematic review. J Natl Cancer Inst. 2012;104:528–40.  https://doi.org/10.1093/jnci/djs027.PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2018

Authors and Affiliations

  1. 1.Department of Molecular PathologyGraduate School of Medicine, Yamaguchi UniversityUbeJapan
  2. 2.Department of PathologyKochi Medical School, Kochi UniversityNankokuJapan

Personalised recommendations